Camrelizumab Biosimilar – Anti-PDCD1, PD-1, CD279 mAb – Research Grade

Description of Camrelizumab Biosimilar - Anti-PDCD1, PD-1, CD279 mAb - Research Grade

Introduction to Camrelizumab Biosimilar – A Revolutionary Anti-PDCD1, PD-1, CD279 mAb Camrelizumab Biosimilar is a novel monoclonal antibody (mAb) that has gained significant attention in the field of immunotherapy. It is a biosimilar version of the well-known anti-PDCD1, PD-1, CD279 mAb, which has been widely used as a therapeutic agent for various types of cancer. This biosimilar version is designed to have similar structure, activity, and application as the original mAb, making it a promising option for cancer treatment. In this article, we will explore the structure, activity, and application of Camrelizumab Biosimilar in detail.

Structure of Camrelizumab Biosimilar

Camrelizumab Biosimilar is a recombinant humanized IgG4 monoclonal antibody that specifically targets PD-1, a receptor found on the surface of T cells. It is composed of two heavy chains and two light chains, each containing variable and constant regions. The variable regions of the antibody are responsible for binding to PD-1, while the constant regions determine the effector functions of the antibody.

Activity of Camrelizumab Biosimilar Camrelizumab Biosimilar exerts its anti-

cancer activity by binding to PD-1 on the surface of T cells and blocking its interaction with its ligands, PD-L1 and PD-L2. This interaction is crucial for the suppression of T cell activity, which is a mechanism used by cancer cells to evade the immune system. By blocking this interaction, Camrelizumab Biosimilar restores the function of T cells, allowing them to recognize and attack cancer cells. This results in the activation of the immune system and destruction of cancer cells, leading to tumor regression.

Application of Camrelizumab Biosimilar

Camrelizumab Biosimilar has been approved for the treatment of various types of cancer, including advanced or metastatic non-small cell lung cancer, classical Hodgkin lymphoma, and hepatocellular carcinoma. It has also shown promising results in clinical trials for other types of cancer, such as melanoma, gastric cancer, and esophageal squamous cell carcinoma.

In addition to its use as a monotherapy, Camrelizumab Biosimilar has also been studied in combination with other cancer treatments, such as chemotherapy, targeted therapy, and other immunotherapies. These combinations have shown synergistic effects, leading to improved outcomes for patients.

Conclusion

In summary, Camrelizumab Biosimilar is a revolutionary anti-PDCD1, PD-1, CD279 mAb that has the potential to significantly improve the treatment of various types of cancer. Its similar structure, activity, and application to the original mAb make it a promising option for cancer therapy. With its approval for multiple indications and ongoing research in combination with other treatments, Camrelizumab Biosimilar has the potential to become a key player in the field of immunotherapy.

Camrelizumab Biosimilar - Anti-PDCD1, PD-1, CD279 mAb binds to CD279 Recombinant Protein in indirect ELISA Assay

Immobilized CD279 Recombinant Protein (cat. No.PX-P4117) at 0.5µg/mL (100µL/well) can bind to Camrelizumab Biosimilar - Anti-PDCD1, PD-1, CD279 mAb (cat. No.PX-TA1445) in indirect ELISA with Goat Anti-Human IgG secondary antibody coupled with HRP measured by OD450